[{"from": "human", "value": "Based on the given information, design a molecule that meets the desired specifications. The molecule is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics."}, {"from": "gpt", "value": "[C][C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=N][C][=C][Branch1][=Branch2][C][C][C][C][C][C][Ring1][Branch2][C][=Branch1][Ring2][=C][Ring1][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F]"}]